Cardinal Health's Leerink Presentation Reiterates Growth Amid DeepValue's Critical Warnings

What happened

Cardinal Health presented at the Leerink Global Healthcare Conference, where management likely emphasized progress in specialty and MSO platforms to sustain investor optimism. This follows repeated guidance hikes, including FY26 non-GAAP EPS of at least $10 and specialty revenue above $50B, driven by recent acquisitions like Solaris Health. However, the DeepValue master report cautions that earnings quality is deteriorating, with a widening GAAP to non-GAAP gap due to $464M in amortization and $126M in acquisition costs in FY25. Critical risks such as CVS concentration at 30% of revenue, rising leverage, and IRA-driven margin pressures remain unaddressed in such promotional events. Thus, the presentation reinforces the bullish narrative but fails to alleviate fundamental concerns about overvaluation and hidden vulnerabilities.

Implication

The Leerink presentation serves to maintain momentum by highlighting specialty growth and EPS targets, but it does not provide new data to justify the stock's elevated valuation. Management's focus on non-GAAP metrics masks the reality of stagnant GAAP earnings and increasing acquisition-related burdens that could cap true economic value. With the stock trading at ~22x FY26 non-GAAP EPS and negative book equity, any deviation from guidance or integration missteps could trigger sharp de-rating from crowded momentum holders. Investors must closely monitor upcoming quarterly results for signs of segment profit slowdown or leverage issues, as per the DeepValue report's 90-day checkpoints. Ultimately, the implication is to hold small or trim exposure above $210-$230, as the risk/reward skews negatively without material changes to the underlying thesis.

Thesis delta

The presentation does not shift the investment thesis; it merely confirms Cardinal Health's commitment to its growth strategy without addressing core weaknesses. The DeepValue report's 'POTENTIAL SELL' rating remains intact, as earnings quality erosion, customer concentration, and policy risks persist unchanged. No new catalysts or risks emerged from this event, reinforcing the view that the stock is overvalued and prone to downside if growth normalizes.